Comparison of Sirolimus with Azathioprine in a Tacrolimus-based Immunosuppressive Regimen in Lung Transplantation
- 1 February 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 183 (3) , 379-387
Abstract
Rationale: Lung transplantation has evolved into a life-saving therapy for select patients with end-stage lung diseases. However, long-term survival remains limited because of chronic rejection. Sirolimus is beneficial in preventing cardiac rejection and may decrease rejection after lung transplantation. Objectives: To determine the potential benefit versus risk of sirolimus in lung transplantation. Methods: We conducted a multicenter randomized, open label controlled trial comparing sirolimus (SIR) with azathioprine (AZA) in a tacrolimus-based immunosuppressive regimen in lung transplantation. The primary end point was the incidence of acute rejection at 1 year after transplantation between the two study groups. Measurements and Main Results: One hundred eighty-one patients were randomized to be included in this study. At 1 year after transplantation, there was no significant difference in the incidence of grade A acute rejection between the two study groups. Similarly, the incidence of chronic rejection and graft survival was no different between the two study groups. Cytomegalovirus infection was decreased in the SIR arm compared with the AZA arm (relative risk, 0.67 [95% confidence interval, 0.55, 0.82]; P < 0.01). There was a higher rate of adverse events leading to early discontinuation of SIR (64%) compared with AZA (49%) during the course of this study. Conclusions: Sirolimus, an mTOR inhibitor, did not decrease the incidence of acute rejection at 1 year compared with azathioprine in lung transplantation. These results differ from previous results in cardiac and renal transplantation and emphasize the need for multicenter randomized controlled trials in lung transplantation. Clinical trial registered with www.clinicaltrials.gov (NCT 00321906).Keywords
This publication has 38 references indexed in Scilit:
- The Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Lung and Heart-Lung Transplantation Report—2009The Journal of Heart and Lung Transplantation, 2009
- 154: Long Term Follow-Up in the AIRSAC Trial, a Multicenter Randomized Clinical Trial in Lung Transplant RecipientsThe Journal of Heart and Lung Transplantation, 2009
- Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinomaLiver Transplantation, 2008
- Antiproliferative Agents Alter Vascular Plasminogen Activator Inhibitor-1 ExpressionArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- The role and value of sirolimus administration in kidney and liver transplantationClinical Transplantation, 2006
- Comparison of Mycophenolate Mofetil and Azathioprine for Prevention of Bronchiolitis Obliterans Syndrome in De Novo Lung Transplant RecipientsTransplantation, 2006
- Conversion to Sirolimus and Mycophenolate Can Attenuate the Progression of Bronchiolitis Obliterans Syndrome and Improves Renal Function after Lung TransplantationTransplantation, 2006
- Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant RecipientsNew England Journal of Medicine, 2003
- Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantationTransplantation, 2003
- Obliterative bronchiolitis after lung and heart-lung transplantationThe Journal of Thoracic and Cardiovascular Surgery, 1995